225 related articles for article (PubMed ID: 12109031)
1. [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)].
Pöpperl G; Götz C; Gildehaus FJ; Yousry TA; Reulen HJ; Hahn K; Tatsch K
Nuklearmedizin; 2002 Jun; 41(3):120-8. PubMed ID: 12109031
[TBL] [Abstract][Full Text] [Related]
2. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors.
Riva P; Arista A; Franceschi G; Frattarelli M; Sturiale C; Riva N; Casi M; Rossitti R
Cancer Res; 1995 Dec; 55(23 Suppl):5952s-5956s. PubMed ID: 7493376
[TBL] [Abstract][Full Text] [Related]
3. Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma.
Pöpperl G; Götz C; Rachinger W; Schnell O; Gildehaus FJ; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):792-800. PubMed ID: 16550381
[TBL] [Abstract][Full Text] [Related]
4. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
Paganelli G; Bartolomei M; Ferrari M; Cremonesi M; Broggi G; Maira G; Sturiale C; Grana C; Prisco G; Gatti M; Caliceti P; Chinol M
Cancer Biother Radiopharm; 2001 Jun; 16(3):227-35. PubMed ID: 11471487
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
[TBL] [Abstract][Full Text] [Related]
6. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.
Goetz C; Riva P; Poepperl G; Gildehaus FJ; Hischa A; Tatsch K; Reulen HJ
J Neurooncol; 2003 May; 62(3):321-8. PubMed ID: 12777085
[TBL] [Abstract][Full Text] [Related]
7. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2.
Riva P; Arista A; Sturiale C; Moscatelli G; Tison V; Mariani M; Seccamani E; Lazzari S; Fagioli L; Franceschi G
Int J Cancer; 1992 Apr; 51(1):7-13. PubMed ID: 1373410
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
[TBL] [Abstract][Full Text] [Related]
9. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
10. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.
Brouwers AH; Mulders PF; de Mulder PH; van den Broek WJ; Buijs WC; Mala C; Joosten FB; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
J Clin Oncol; 2005 Sep; 23(27):6540-8. PubMed ID: 16170161
[TBL] [Abstract][Full Text] [Related]
11. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
McLendon RE; Akabani G; Friedman HS; Reardon DA; Cleveland L; Cokgor I; Herndon JE; Wikstrand C; Boulton ST; Friedman AH; Bigner DD; Zalutsky MR
Nucl Med Biol; 2007 May; 34(4):405-13. PubMed ID: 17499730
[TBL] [Abstract][Full Text] [Related]
12. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
[TBL] [Abstract][Full Text] [Related]
13. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors.
Riva P; Arista A; Tison V; Sturiale C; Franceschi G; Spinelli A; Riva N; Casi M; Moscatelli G; Frattarelli M
Cancer; 1994 Feb; 73(3 Suppl):1076-82. PubMed ID: 8306250
[TBL] [Abstract][Full Text] [Related]
14. Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors.
Marriott CJ; Thorstad W; Akabani G; Brown MT; McLendon RE; Hanson MW; Coleman RE
J Nucl Med; 1998 Aug; 39(8):1376-80. PubMed ID: 9708511
[TBL] [Abstract][Full Text] [Related]
15. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors.
Wygoda Z; Kula D; Bierzyńska-Macyszyn G; Larysz D; Jarzab M; Właszczuk P; Bazowski P; Wojtacha M; Rudnik A; Stepień T; Kaspera W; Etmańska A; Składowski K; Tarnawski R; Kokocińska D; Jarzab B
Hybridoma (Larchmt); 2006 Jun; 25(3):125-32. PubMed ID: 16796458
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
[TBL] [Abstract][Full Text] [Related]
19. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA; Zalutsky MR; Akabani G; Coleman RE; Friedman AH; Herndon JE; McLendon RE; Pegram CN; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Guruangan S; Boulton S; Raynor RH; Dowell JM; Wong TZ; Zhao XG; Friedman HS; Bigner DD
Neuro Oncol; 2008 Apr; 10(2):182-9. PubMed ID: 18287339
[TBL] [Abstract][Full Text] [Related]
20. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
